v3.25.4
Revenues (Tables)
12 Months Ended
Dec. 31, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of Product Revenue The table below presents the Company’s gross and net product revenue ($ in thousands):
Year Ended December 31,
202520242023
Product revenue - gross496,232 423,855 298,911 
Less: Rebates and sales returns(39,050)(26,241)(32,192)
Product revenue - net457,182 397,614 266,719 
Schedule of Disaggregation of Net Revenue
The following table presents the Company’s net revenue by commercial program ($ in thousands):
Year Ended December 31,
202520242023
ZEJULA189,042 187,082 168,843 
VYVGART / VYVGART Hytrulo
94,198 93,639 10,011 
NUZYRA60,836 43,199 21,656 
OPTUNE48,325 40,475 46,969 
QINLOCK35,614 28,826 19,240 
XACDURO22,912 3,305 — 
AUGTYRO5,538 1,088 — 
Other (i)717 — — 
Product revenue - net457,182 397,614 266,719 
(i)Other includes product candidates sold in patient programs prior to commercialization.